ABSTRACT
Purpose: To report the incidence, clinical features, potential risk factors, and outcomes of intraocular inflammation (IOI) following brolucizumab in Indian eyes. Methods: All consecutive patients diagnosed with brolucizumab?induced IOI from 10 centers in eastern India between October 2020 and April 2022 were included. Results: Of 758 injections given during the study period across centers, 13 IOI events (1.7%) were recorded attributable to brolucizumab. The IOI occurred after the first dose in two eyes (15%) (median 45 days after brolucizumab), second dose in six eyes (46%) (median = 8.5 days), and third dose (39%) in the remaining five eyes (median 7 days). Reinjections of brolucizumab were administered at a median interval of 6 weeks (interquartile range = 4–10 weeks) in the 11 eyes, where IOI occurred after the second or third dose. Eyes that experienced IOI after the third dose had received a significantly greater number of previous antivascular endothelial growth factor injections (median = 8) compared to those who developed it after the first or second dose (median = 4) (P = 0.001). Anterior chamber cells were seen in almost all eyes (n = 11, 85%), while peripheral retinal hemorrhages were seen in two eyes, and one eye showed branch artery occlusion. Two?thirds of patients (n = 8, 62%) recovered with a combination of topical and oral steroids, while remaining recovered with topical steroids alone. Irreversible visual loss was not seen in any eye, and median vision recovered to pre?IOI levels by 3 months’ time point. Conclusion: Brolucizumab?induced IOI was relatively rare, occurring in 1.7% of eyes, was more common after the second or third injection, especially in those who required frequent reinjections every 6 weeks, and occurred earlier with increasing number of previous brolucizumab injections. Continued surveillance is necessary even after repeated doses of brolucizumab.
ABSTRACT
Purpose: To report the initial experience of managing treatment?resistant and treatment?na飗e eyes with polypoidal choroidal vasculopathy (PCV) by using brolucizumab 6 mg. Methods: This was a retrospective multicentric series of all consecutive eyes with PCV treated with brolucizumab. Treatment resistance was defined as taking at least six prior anti?VEGF injections over the past 1 year and showing persistent disease activity in the form of intra (IRF) or subretinal fluid (SRF) or both. All patients were treated on a pro re nata (PRN) basis and followed up monthly. Retreatment was considered when either SRF or IRF were present at any time point during the study. Results: We included 21 eyes of 21 patients with PCV with a mean age of 65.1 � 9.9 years, of which 16 eyes (76%) were treatment?resistant. The mean follow?up period from receiving the first brolucizumab was 27.3 � 3.3 weeks. Of the 21 eyes, seven eyes (33%) received three injections during follow?up, 13 eyes (62%) received two injections, and one eye received one injection. The mean injection?free interval was 12 � 1.2 weeks. The median pretreatment vision was 0.6 logMAR (IQR = 0.47�logMAR) and improved to 0.3 logMAR (IQR = 0.25�6 logMAR), whereas the mean macular thickness improved from 443 � 60 ?m at baseline to 289 � 25 ?m (P < 0.001) at the last follow?up period. None of the eyes experienced any intraocular inflammation across 48 injection sessions. Conclusion: Brolucizumab is safe and effective in controlling PCV disease in both treatment?resistant and treatment?na飗e eyes
ABSTRACT
White spot syndrome virus (WSSV), is the most contagious pathogen of cultured shrimp that causes mass mortality, leading to huge economic loss to the shrimp industry. The lack of effective therapeutic or prophylactic measures has aggravated the situation, necessitating the development of antiviral drugs. With this objective, the antiviral activity of the drug, (MP07X -derived from the marine plant) in the host, Litopenaeus vannamei was evaluated. The biochemical changes aggravated by WSSV in the host, and the in vivo efficacy of the drug in the host – pathogen interaction were analyzed. The survival percentage of the treated (with MP07X) WSSV infected host was 85 %. Significant results were obtained from the cytotoxicity assays of the drug in both the brine shrimp and host. A total of 9 biochemical parameters such as, total protein, total carbohydrate, total glucose, total free amino acid, total fatty acid, fructose 1, 6 diphosphatase, aldolase, glucose 6 phosphatase and glucose 6 phosphate dehydrogenase were examined for healthy (NEG), WSSV infected (POS) and test sample (TS) shrimps. Significant differences (p < 0.01) were observed between the POS, NEG and TS in the biochemical variables at different time intervals post infection with WSSV. In the case of POS, significantly (p < 0.01) reduced variables were observed when compared to the NEG. In contrast, significant (p < 0.01) elevations were observed in the TS after a certain time interval due to the anti-WSSV activity of MP07X. Neither the VP 28 gene nor the immediate early genes (ie 1) were expressed in the host at the 42nd and 84th hrs. Thus, in accordance with the above results it can be concluded that acute WSSV infection triggers alterations in biochemical parameters in L. vannamei and at the same time the drug is efficient enough to combat the deadly virus and can increase the survivability of the host.
ABSTRACT
Presently an effort has been made to determine the effectiveness of probiotics against marine pathogenic bacterial load ingested by Artemia franciscana nauplii. In this experiment Artemia franciscana nauplii was allowed to ingest pathogenic bacterial strains, viz. Escherichia coli, Salmonella typhi, Salmonella paratyphi, Vibrio cholerae and Shigella sp. Probiotic organism (Bioremid) was used against the pathogenic strains on Artemia franciscana nauplii. On completion of the experiment it was observed that the use of Probiotic organism (Bioremid) reduced the pathogenic bacterial load, especially that of Shigella sp. on Artemia franciscana.